Andrew Lees, Fina Biosolutions’ scientific director, speaks on the challenges of purifying conjugate vaccines and vaccine components. Ion Exchange: Pore choices and ion clouds: aspects of resin architecture that affect…
Last month, the Maryland Tech Council stopped by Fina Biosolutions, where they met with Founder, CEO and Chief Scientific Officer, Dr. Andrew Lees. Dr. Lees was a gracious host, giving…
Fina Biosolutions licenses CRM197 vaccine component to PATH for use in low-income countries November 15, 2018 06:00 AM Eastern Standard Time ROCKVILLE, Md. - Fina Biosolutions LLC announced today it has reached agreement…
Over the summer, we replaced FinaBio’s ancient ultracold freezers with two new Panasonic freezers from PHC. John Bergen, now the regional manager for PHC, has been trying to sell to…
Proprietary method of producing CRM197 will be used to develop affordable vaccines for children and adults in developing nations Rockville, MD., September 27, 2018–Fina Biosolutions announces that the United States…
Meet with Fina Biosolutions through the BIO One-on-One Partnering at BIO2018. Fina Biosolutions will be at BIO 2018 in Boston June 4-7 2018. We will have a stand in the…
On February 1, 2018, Andrew Lees spoke at the Keystone meeting, Emerging Technologies in Vaccine Discovery and Development, held in Banff, Alberta, Canada. He chaired the session, “New Tools in…
“The Medicine Maker Power List hails one hundred of the best and brightest individuals involved in drug development. It’s fair to say that the pharmaceutical industry is not always looked upon favourably by the public,…
Fina Biosolutions is pleased to offer EcoCRMTM, economical CRM197 from E. coli, to the research and vaccine manufacturing community. CRM197, a genetically detoxified diphtheria toxin, is widely used as a…
Dr. Andrew Lees, founder and Chief Scientific Officer of Fina Biosolutions, has been named to The Power List 2016 – the Top 100 most influential people in the world of…